*Result*: Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
*Author/editor-in-chief*:
Le Tourneau, Christophe (Verfasser); Becker, Heiko (Verfasser) ; Claus, Rainer (Verfasser) ; Elez, Elena (Verfasser); Ricci, Federico (Verfasser); Fritsch, Ralph (Verfasser) ; Silber, Y. (Verfasser); Hennequin, Audrey (Verfasser); Tabernero, Josep (Verfasser); Jayadeva, Girish (Verfasser); Lüdtke, Doreen (Verfasser) ; He, M. (Verfasser); Isambert, Nicolas (Verfasser)
*Publication*:
Freiburg : Universität, 2022
*Physical description scale*:
1 Online-Ressource
*Format*:
*Language*:
*eng*
*Notes*:
ESMO open. - 7, 5 (2022) , 100576, ISSN: 2059-7029
*DOI*:
10.1016/j.esmoop.2022.100576